English (international)
Eesti
Български
Deutsch
Français
Español (Latinoamérica)
Polski
Magyar
Română
Lexicon Pharmaceuticals Inc
Fermé
Secteur Soins de santé
1.6
Résumé
Variation du prix de l'action
24h
Min
1.6
Max
1.61
Revenu | -51M |
|---|---|
Ventes | 540K 702K |
BPA | -0.2 |
Marge bénéficiaire | -31,188.272 |
Employés | 285 |
EBITDA | -49M |
Recommandations | Achat Fort |
|---|---|
Prévisions sur 12 Mois | +417.39 upside |
Capitalisation Boursière | -1.2M 510M |
|---|---|
Ouverture précédente | 1.6 |
Clôture précédente | 1.6 |
Score Technique
By Trading Central
Confiance
Very Strong Bearish Evidence
Lexicon Pharmaceuticals Inc Graphique
Actualités Associées
Comparaison
Variation de prix
Lexicon Pharmaceuticals Inc prévision
Objectif de Prix
By TipRanks
417.39% hausse
Prévisions sur 12 Mois
Moyen 8.33 USD 417.39%
Haut 10 USD
Bas 5 USD
Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.
Éléments financiers
Frais Généraux et Administratifs
Dépenses d'exploitation
Résultat avant impôt
Ventes
Coût des ventes
Marge brute des ventes
Charges d'intérêt sur la dette
EBITDA
Bénéfice d'exploitation
$
À Propos Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of treatments for human diseases. The Company's drug programs include Sotagliflozin, LX9211 and LX2761. LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of type I diabetes and type II diabetes, heart failure and chronic kidney disease. LX2761 is an orally-delivered small molecule compound that is designed to inhibit sodium-glucose cotransporter 1 (SGLT1) locally in the gastrointestinal tract without any inhibition of sodium-glucose cotransporter 2 (SGLT2) in the kidney.
